Zoom has some problems besides all the lawsuits And I do

New Post Public Reply Private Reply Replies (3) Message Board
redspeed manfromjax #19318
566
Zoom has some problems besides all the lawsuits

And I do mean more than one...

BTW, these are real lawsuits

https://www.abajournal.com/news/article/anoth...y-problems

They said their customer base was enterprises

But that customer base was responsible to make Zoom solution secure

Huh?

I guess if you own a house, you are responsible for the security and locks on the doors

But what ever it was someone else's house?

How exactly to you make their own app secure

You didn't build it

You don't have the blueprints

Do you want to pay a lot of money to test it?

Hell know, that's the SaaS vendors job

No enterprise in their right mind is going to sign up for Zoom until those issues are fixed

Even then, they have the negative overhang

We not only screwed up, but we kept it all a secret...

No, deflector shields went up

We never intended to provide industry standard security

That's up to you

I never saw Microsoft, Oracle and IBM pass the buck like this

I guess what could they say?


What made them popular is the ease of use, is now coming back to bite them

If you are an enterprise, you are now working on moving off their system now the truth comes out

So they said the consumer segment was never their intended user base

You know why?

Because they don't pay

Want to chat with your buddy's?

Hey, Zoom is free!

Giving away 90% of you business or whatever the number is, is not sustainable

Especially if some of the paying enterprise customers, go away

Especially if new enterprises hesitate to sign up

Servers, bandwidth and other resources are not free

If you think your internet bill is high, keep in mind, companies pay for that same bandwidth it to come out of their datacenters and it's not $49/mo

You pay for the volume of data going out...

Zoom infrastructure bills have to be through the roof

Money 101

You can't lose money giving away a lot for free and make it up in volume

Read their filings

Their freemium model is well discussed

It will be very interesting to see their Q1 and especially the Q2 numbers

In these crazy times, it's going to be hard to predict but...

Have expectations on Zoom been over set?

Keep in mind I posted an institution that totally sold out of Zoom, but bought VERB

I wish them the best as one day VERB might license some of their tech to them

TON Strategy Co. (TONX) Stock Research Links

TONX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytokinetics Faces Class Action: What You Need to Know

Updated Category News Views 175

Understanding the Class Action Lawsuit Against Cytokinetics Cytokinetics, Incorporated is currently facing a significant class action lawsuit initiated by shareholders. This legal challenge brings to light serious allegations against the Company regarding their disclosures and expectations for FDA approval of a key drug. Details of the Allegations The lawsuit asserts that...

Continue Reading
Discover the Embodied Luxury of the Champagne Specialist Course

Updated Category News Views 207

Verona Hosts the Esteemed Champagne Specialist Course The Italian Wine Academy is excited to announce a remarkable opportunity for wine enthusiasts and professionals. In Verona, for the very first time, the Academy will conduct the prestigious Comité Champagne 'Champagne Specialist' course. This unique program will be available in both English and Italian, providing an...

Continue Reading
MiniLuxe Achieves Strong Q1 2025 Growth with Strategic Focus

Updated Category News Views 378

MiniLuxe Reports Strong Financial Performance for Q1 2025 Reported figures all in U.S. Dollars MiniLuxe Holding Corp. (TSXV: MNLX) has announced exciting financial results for its first quarter of the year. This period showcased a significant 9% growth in revenue, reaching an impressive $6.1 million. Coupled with a gross profit of $2.5 million, reflective of a 12%...

Continue Reading
Transforming Shopify: AI Product Discovery for Enterprises

Updated Category News Views 141

Fredhopper's New App for Shopify Fredhopper Introduces Cutting-Edge Product Discovery Solutions The ecommerce landscape is evolving rapidly, and innovation is at the forefront. Fredhopper has launched its Product Discovery App for Shopify, bringing advanced AI-powered product search and personalized recommendations directly into the hands of enterprise merchants. This...

Continue Reading
Quantum Computing Inc. Faces Class Action Lawsuit for Shareholders

Updated Category News Views 162

Understanding the Recent Class Action Against Quantum Computing Inc. In a significant turn of events, Quantum Computing Inc. has come under legal pressure as a class action lawsuit has been filed on behalf of its shareholders. The lawsuit comes in response to allegations of misleading information that may have adversely affected investors' financial interests. Class...

Continue Reading